CN109963874A - 靶向并通过辐射能分解癌症的癌症结合着色肽 - Google Patents

靶向并通过辐射能分解癌症的癌症结合着色肽 Download PDF

Info

Publication number
CN109963874A
CN109963874A CN201780071480.2A CN201780071480A CN109963874A CN 109963874 A CN109963874 A CN 109963874A CN 201780071480 A CN201780071480 A CN 201780071480A CN 109963874 A CN109963874 A CN 109963874A
Authority
CN
China
Prior art keywords
cancer
radiant energy
wavelength
compound
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780071480.2A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·D·延森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cao Group Inc
Original Assignee
Cao Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cao Group Inc filed Critical Cao Group Inc
Publication of CN109963874A publication Critical patent/CN109963874A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780071480.2A 2016-10-26 2017-10-25 靶向并通过辐射能分解癌症的癌症结合着色肽 Pending CN109963874A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662412938P 2016-10-26 2016-10-26
US62/412,938 2016-10-26
PCT/US2017/058267 WO2018081254A1 (en) 2016-10-26 2017-10-25 Cancer binding chromatic peptides that are targeted for disintegration by radiant energy

Publications (1)

Publication Number Publication Date
CN109963874A true CN109963874A (zh) 2019-07-02

Family

ID=62025444

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780071480.2A Pending CN109963874A (zh) 2016-10-26 2017-10-25 靶向并通过辐射能分解癌症的癌症结合着色肽

Country Status (4)

Country Link
US (1) US20190275173A1 (enExample)
JP (1) JP2019534286A (enExample)
CN (1) CN109963874A (enExample)
WO (1) WO2018081254A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111484442B (zh) 2018-06-01 2021-11-09 杭州阿诺生物医药科技有限公司 一种具有抗肿瘤活性的csf1r抑制剂中间体的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010558A1 (en) * 2010-07-09 2012-01-12 Services, National Institutes of Health Photosensitizing antibody-fluorophore conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080058785A1 (en) * 2006-04-12 2008-03-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Autofluorescent imaging and target ablation
US20100183504A1 (en) * 2007-06-14 2010-07-22 Fanqing Frank Chen Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
JP6192799B2 (ja) * 2013-03-15 2017-09-06 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 腫瘍の標的画像化に使用される化合物にコンジュゲートしているアミノ酸連結基の合成および組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010558A1 (en) * 2010-07-09 2012-01-12 Services, National Institutes of Health Photosensitizing antibody-fluorophore conjugates

Also Published As

Publication number Publication date
WO2018081254A1 (en) 2018-05-03
JP2019534286A (ja) 2019-11-28
US20190275173A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
Khalkhal et al. The evaluation of laser application in surgery: a review article
ES2266073T3 (es) Dispositivo para determinar la perfusion de tejidos.
US6443976B1 (en) Methods for treating conditions and illnesses associated with abnormal vasculature
Bown Photodynamic therapy for photochemists
US6416531B2 (en) Application of light at plural treatment sites within a tumor to increase the efficacy of light therapy
US20100305436A1 (en) Systems, devices, and methods for photoactive assisted resection
CN104800863A (zh) 用于神经成像的包括与病毒组分结合的荧光染料的成像法和组合物
EP3231480A1 (en) Treating cancer using electromagnetic fields in combination with photodynamic therapy
EP3919116A1 (en) Methods and systems for reducing neural activity in an organ of a subject
JP2017000737A (ja) 統合された照射を有する外科手術器具
KR20170015570A (ko) 세포 증식 질환을 치료하기 위한 방법 및 시스템
KR20250133984A (ko) 세포-대-세포 통신을 측정 및 유도하기 위한 방법, 장치 및 조성물, 및 이의 치료적 용도
MX2013008957A (es) Dispositivo de diagnostico, dispositivo terapeutico, y usos de los mismos.
JP2005527493A5 (enExample)
US20180093104A1 (en) Light irradiation method, light irradiation device, light irradiation system, device system for photodynamic diagnosis or photodynamic therapy, system for specifying tumor site and system for treating tumor
CN109963874A (zh) 靶向并通过辐射能分解癌症的癌症结合着色肽
US20100004640A1 (en) Cancer Treatment Using Lasers
WO2019244977A1 (ja) 腫瘍治療法
RU2212867C2 (ru) Способ лечения внутриглазных опухолей
Saidi et al. Nonthermal ablation of malignant esophageal strictures: photodynamic therapy, endoscopic intratumoral injections, and novel modalities
CN109963875A (zh) 靶向并通过辐射能分解癌症的癌症结合不透射线肽类
CN111789672A (zh) 一种靶向光学成像辅助的精准切割及治疗的止血手术刀
Forer et al. Dural defect repair with fascia by a CO2 laser system in a porcine model
Bingham Laser principles in otolaryngology, head and neck surgery
JPH11151309A (ja) 癌抑制装置

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190702

WD01 Invention patent application deemed withdrawn after publication